Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matritech's cancer assay gets positive panel review

This article was originally published in Clinica

Executive Summary

The US FDA's Immunology Devices Advisory Panel voted four to three on November 30th in favour of recommending that Matritech's NMP22 assay be approved after additional data in women and blacks is accrued. The NMP22 test kit is an immunoassay for quantitative determination of the level of nuclear protein NMP22 in the urine of patients recently treated for transitional cell bladder cancer. Matritech is developing the MAb kit to aid in the identification of patients at risk for recurrent bladder cancer.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel